HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: FDA cosmetics inspections

This article was originally published in The Rose Sheet

Executive Summary

FDA cosmetics inspections: Agency would phase out field monitoring of cosmetics manufacturing facilities in fiscal 1998 and 1999 with work "continuing at the center level," according to the Administration's FY 1999 budget justification plan for FDA. For fiscal 1998 (ending Sept. 30), the agency's expenditure for monitoring activity has been cut in half; the budget has earmarked $60,000 for facility inspections, $35,000 to analyze domestic samples and another $90,000 to assess import samples. In fiscal 1999, the inspections budget will be eliminated altogether. The cuts come as the agency tries to find funds to meet President Clinton's Food Safety Initiative, and indicate the cosmetics programs will continue to see restraints within the Center for Food Safety & Applied Nutrition...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel